



ASX, NASDAQ and Media Release  
06 March 2024

## **Opthea to Participate in the Leerink Partners Global Biopharma Conference**

Melbourne, Australia, 06 March 2024, and Princeton, New Jersey, 05 March 2024 – Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that management will participate in one-on-one investor meetings at the Leerink Partners Global Biopharma Conference being held in Miami, Florida on March 11-13, 2024.

### **About Opthea**

Opthea (ASX:OPT; NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, [NCT04757636](#), and ShORe, [NCT04757610](#),) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit [our website](#) and follow us on [X](#) and [LinkedIn](#).

**Authorized for release to ASX by Fred Guerard, CEO**

### **Investor Enquiries**

PJ Kelleher  
LifeSci Advisors  
Email: [pkelleher@lifesciadvisors.com](mailto:pkelleher@lifesciadvisors.com)  
Phone: 617-430-7579

### **Media**

Silvana Guerci-Lena  
NorthStream Global Partners  
[silvana@nsgpllc.com](mailto:silvana@nsgpllc.com)

Join our email database to receive program updates:  
Tel: +61 (0) 3 9826 0399,  
Email: [info@opthea.com](mailto:info@opthea.com)